THE DOUBLE BIND
Before his death from pancreatic cancer in 2011, Steve Jobs paid $100,000 to have his DNA sequenced. It was a rare and expensive move that, according to biographer Walter Isaacson, provided insight into potential treatments and allowed doctors to customize his drug regimen. Five years after Jobs’s death, that same kind of sequencing is widely available and costs just a few thousand dollars—or less.
The company most responsible for revolutionizing access to DNA isn’t a household name. Illumina is a $20 billion–plus genomics power-house whose supercomputers have sequenced some 90% of all the DNA data ever processed. Its machines have helped make genomics a compelling tool, used to treat diseases, predict drug responses, and identify which genetic mutations increase our risk of serious illness. They’ve also made it affordable for companies such
You’re reading a preview, subscribe to read more.
Start your free 30 days